• 1. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 2. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962
• 3. Excitonic channels from bio-inspired templated supramolecular assembly of J-aggregate nanowires?
  Daniel Messmer,Stefan Salentinig,Jakob Heier Nanoscale, 2019,11, 6929-6938
• 4. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 5. Dissolution of cork biopolymers in biocompatible ionic liquids
  Helga Garcia,Rui Ferreira,Marija Petkovic,Jamie L. Ferguson,Maria C. Leit?o,H. Q. Nimal Gunaratne,Luís Paulo N. Rebelo Green Chem., 2010,12, 367-369

• Solvents and Organic Chemicals Organic Compounds Alkaloids and derivatives Macroline alkaloids Macroline alkaloids
• Solvents and Organic Chemicals Organic Compounds Alkaloids and derivatives Macroline alkaloids

Introduction to 16-Epikoumidine (CAS No. 124096-81-7)

16-Epikoumidine, with the CAS number 124096-81-7, is a naturally occurring compound that has garnered significant attention in the field of medicinal chemistry and pharmacology. This compound is a derivative of koumidine, a class of compounds found in the plant Kopsia sp.. The unique structural features and biological activities of 16-Epikoumidine have made it a subject of extensive research, particularly in the areas of anti-inflammatory and anti-cancer therapies.

The chemical structure of 16-Epikoumidine is characterized by a complex alkaloid framework, which includes multiple chiral centers and functional groups. These structural elements contribute to its diverse biological activities. Recent studies have highlighted the potential of 16-Epikoumidine in modulating various cellular processes, making it a promising candidate for drug development.

In the context of anti-inflammatory research, 16-Epikoumidine has been shown to exhibit potent inhibitory effects on pro-inflammatory cytokines such as TNF-α and IL-6. These cytokines play crucial roles in the pathogenesis of chronic inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease. The mechanism by which 16-Epikoumidine exerts its anti-inflammatory effects involves the inhibition of nuclear factor-kappa B (NF-κB) activation, a key transcription factor involved in inflammation.

Beyond its anti-inflammatory properties, 16-Epikoumidine has also demonstrated significant anti-cancer activity. Preclinical studies have shown that this compound can induce apoptosis in various cancer cell lines, including those derived from breast, lung, and colon cancers. The anticancer effects of 16-Epikoumidine are attributed to its ability to disrupt cell cycle progression and inhibit angiogenesis, thereby reducing tumor growth and metastasis.

The pharmacokinetic profile of 16-Epikoumidine has been studied to understand its bioavailability and metabolism. Research indicates that this compound has moderate oral bioavailability and is metabolized primarily by the liver through cytochrome P450 enzymes. The metabolic stability and low toxicity profile of 16-Epikoumidine make it an attractive candidate for further clinical development.

Clinical trials are currently underway to evaluate the safety and efficacy of 16-Epikoumidine in treating various diseases. Early results from phase I trials have shown promising outcomes, with patients exhibiting good tolerability and significant improvements in disease symptoms. These findings underscore the potential of 16-Epikoumidine as a novel therapeutic agent.

In addition to its therapeutic applications, 16-Epikoumidine has also been explored for its potential use in combination therapies. Combining this compound with existing drugs can enhance treatment efficacy while reducing side effects. For example, studies have shown that co-administration of 16-Epikoumidine with conventional chemotherapy agents can synergistically inhibit tumor growth and improve patient outcomes.

The future prospects for 16-Epikoumidine are promising. Ongoing research aims to optimize its chemical structure to enhance its potency and selectivity. Additionally, efforts are being made to develop more effective delivery systems to improve its therapeutic index. These advancements are expected to broaden the clinical applications of 16-Epikoumidine.

In conclusion, 16-Epikoumidine (CAS No. 124096-81-7) is a multifaceted compound with significant potential in the treatment of inflammatory and cancerous diseases. Its unique chemical structure and biological activities make it an exciting area of research in medicinal chemistry and pharmacology. As more studies are conducted, it is likely that new applications for this compound will be discovered, further solidifying its importance in the field.

• 47326-53-4((1S,12S)-15-Ethylidene-13-(hydroxymethyl)-17-methyl-3-aza-17-azoniapentacyclo[12.3.1.02,10.04,9.012,17]octadeca-2(10),4(9),5,7-tetraen-7-ol)
• 522-47-4(6,10-Methanoindolo[3,2-b]quinolizine-11-methanol,9-ethylidene-5,6,8,9,10,11,11a,12-octahydro-2-methoxy-,(6S,7R,9E,10R,11R,11aS)-)
• 16049-28-8(Indolo[2,3-a]quinolizine-2-ethanol,b-ethenyl-1,2,3,4,6,7,12,12b-octahydro-,(bR,2S,12bS)-)
• 604-99-9(16-Epikoumidine)
• 126640-98-0(16-Epinormacusine B)
• 6792-07-0(Macusine B)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)